← All trials
NCT05212948
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 25, 2021
- Primary completion
- Mar 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jan 28, 2022
- Last posted
- Jul 28, 2022
- Enrollment
- 54915
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ShionogiLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.